News | May 29, 2007

Sickest Heart Patients May Not Get Treatments They Need

May 30, 2007 -- The Canadian Press reports this week that people in the greatest need of cardiac medications and interventions are less likely than moderately ill patients to get the full range of heart drugs and procedures, and it may be because they fail the "eyeball" test.

Two American cardiologists have suggested that doctors may view these patients, the sickest of the sick, as too ill to benefit from invasive treatments like catheterization or too depressed or unwell to deal with the hassle of more medication in what is likely already a multi-pill daily regime.

Dr. John Spertus of the University of Missouri, Kansas City and Dr. Mark Furman of the University of Massachusetts Medical School express their views in an editorial in the "Archives of Internal Medicine."

Their editorial accompanies two studies by Canadian research teams that found that sicker patients were less likely to be getting an important cholesterol lowering drug called a statin or to undergo cardiac catheterization.

The studies add support to what's called the treatment-risk paradox, a phenomenon first described by researchers at Toronto's Institute for Clinical Evaluative Studies.

They reported in 2004 that patients who would benefit most from cardiac interventions were least likely to be getting them.


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now